SOHO Italy 1st School of Acute Leukemia

 

SOHO Italy 1st School of Acute Leukemia
Avatar

How Do I Manage Ph-Like ALL at MD Anderson: HCVAD + Ofatumumab, Testing Algorithm, TKI Trials, New mAb Drugs, alloSCT, and Current Clinical Practice

By SOHO Italy 1st School of Acute Leukemia FEATURING Marina Konopleva
By SOHO Italy 1st School of Acute Leukemia FEATURING Marina Konopleva
0 views
April 14, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Videos
13:35
SOHO Italy 1st School of Acute Leukemia

The Road to AML: A Clinical and Biological Overview

Feat. S. Galimberti
07:52
SOHO Italy 1st School of Acute Leukemia

AML Molecular Pathogenesis & Approach to Therapeutic Targets

Feat. S. Galimberti
10:49
SOHO Italy 1st School of Acute Leukemia

FLT3m AML: Midostaurin + Chemo, Sorafenib Maintenance After Allo-HSC…

Feat. G. Martinelli
25:10
SOHO Italy 1st School of Acute Leukemia

AML in 2021: MD Anderson Perspective on Progress in Research and The…

Feat. H. Kantarjian
20:05
SOHO Italy 1st School of Acute Leukemia

Optimizing FLT3i Use in FLT3+ AML in 2021: What Are the Current and …

Feat. N. Daver
15:43
SOHO Italy 1st School of Acute Leukemia

2021 AML Drugs in EU: Microenvironment & Parasite Relations, Pot…

Feat. G. Martinelli
16:03
SOHO Italy 1st School of Acute Leukemia

2021 Updates on the Role of Maintenance in AML: Stem Cell Modeling, …

Feat. M. Gottardi
15:53
SOHO Italy 1st School of Acute Leukemia

Role of SCT in AML: Choice of Donor, HSCT in Active Disease, Older P…

Feat. A. Olivieri
14:48
SOHO Italy 1st School of Acute Leukemia

Environment-Mediated Drug Resistance in AML: Is Targeting CAMDR a Ne…

Feat. C. Cerchione
09:40
SOHO Italy 1st School of Acute Leukemia

Role of Single Agent IDHi in AML: Effects on Hematopoiesis, Ena/Ivo …

Feat. M. Paola Martelli
05:02
SOHO Italy 1st School of Acute Leukemia

IDH1/2 Inhibitor Combinations for AML: Ivo/Ena+Aza for Newly Diagnos…

Feat. M. Paola Martelli
14:25
SOHO Italy 1st School of Acute Leukemia

2021 Updates on Ph+ ALL: Chemo+Dasatinib, Dasatinib vs. Imatinib in …

Feat. E. Jabbour
12:15
SOHO Italy 1st School of Acute Leukemia

Integrating IO in the Frontline ALL: Hyper-CVAD+Ponatinib, Blina+Ino…

Feat. E. Jabbour
16:56
SOHO Italy 1st School of Acute Leukemia

Novel Antibodies in AML: What Is the Role of Gemtuzumab Ozogamicin? …

Feat. F. Ravandi
16:41
SOHO Italy 1st School of Acute Leukemia

AML Management: Strategies to Integrate IO & Targeted Therapies

Feat. N. Daver
13:23
SOHO Italy 1st School of Acute Leukemia

CAR-T Based Approach in ALL: Humanized CAR-T, Fast-Off Rate Low-Affi…

Feat. J. Ribera
07:44
SOHO Italy 1st School of Acute Leukemia

How Do I Manage Ph-Like ALL at MD Anderson: HCVAD + Ofatumumab, Test…

Feat. M. Konopleva
05:05
SOHO Italy 1st School of Acute Leukemia

How Do I Manage ETP ALL at MD Anderson: Hyper-CVAD + Nelarabine, Hyp…

Feat. M. Konopleva
24:35
SOHO Italy 1st School of Acute Leukemia

CD19 Cells in Childhood & Adult ALL Relapsed After ASCT: Anti-CD…

Feat. A. Rambaldi
20:15
SOHO Italy 1st School of Acute Leukemia

Role of mAbs in R/R ALL: INO vs. SoC, INO for B-Cell Disease Eligibl…

Feat. F. Lanza
14:08
SOHO Italy 1st School of Acute Leukemia

2021 ALL Updates: Disease Identification Markers, INO vs. SoC in R/R…

Feat. G. Martinelli
21:41
SOHO Italy 1st School of Acute Leukemia

2021 Updates on MRD Assessment and Impact on AML: MRD Monitoring, EL…

Feat. F. Buccisano
19:42
SOHO Italy 1st School of Acute Leukemia

How I Manage ALL in 2021: Can Adult Ph+ Patients Achieve CMR With Da…

Feat. G. Martinelli
26:39
SOHO Italy 1st School of Acute Leukemia

2021 MD Anderson Updates on ALL: Treatment Comparison by Age and Dis…

Feat. H. Kantarjian